MoMelan Technologies, the developer of a device to treat skin disorders by expanding the surface area of skin grafts, has raised $3.5 million, according to the company’s top executive. MoMelan, based in Cambridge, MA, added KLP Enterprises and Life Science Angels to its existing list of investors, which includes LaunchCapital and Mass Medical Angels. The company will use the Series A money to further develop its device and conduct clinical studies, with the goal of a limited market release in the next 18 months, co-founder and president Sameer Sabir told Xconomy.
